TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01565564

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared glycaemic control care within the local three-tier's antenatal care network
Description: * Individualized dietary and physical activity consultation plus group diabetes education~* Self blood glucose monitoring~* Insulin therapy if indicated~* Self blood glucose monitoring~* Insulin therapy institutions if indicated;

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared glycaemic control care within the local three-tier's antenatal care network
Description: * Individualized dietary and physical activity consultation plus group diabetes education~* Self blood glucose monitoring~* Insulin therapy if indicated~* Self blood glucose monitoring~* Insulin therapy institutions if indicated;
Study: NCT03453866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warmed Arthroscopic Fluids
Description: Warmed Arthroscopic Fluids

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Room Temperature Arthroscopic Fluids
Description: Room Temperature Arthroscopic Fluids
Study: NCT03582904

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: real or sham tDCS delivered to primary motor cortex

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: real or sham tDCS delivered to primary motor cortex
Study: NCT03781791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Investigational Treatment ENT-01
Description: ENT-01 will be administered in tablet form, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Treatment
Description: Placebo will be administered in tablet form, once daily.
Study: NCT00276614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study: NCT03324425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80mg
Description: Participants will receive simvastatin 80 mg by mouth daily at bedtime
Study: NCT04469231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Discectomy & Fusion
Description: ACDF
Study: NCT00806442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Borage Seed Oil and Echium Seed Oil
Description: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn Oil
Description: 9 g/day of corn oil
Study: NCT02692599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: investigational live attenuated mumps vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
Study: NCT03945019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13 SC (Infliximab)
Description: Subcutaneous injection of CT-P13 SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Subcutaneous injection of Placebo SC
Study: NCT05729698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baby warmer swaddle
Description: Baby Swaddle with Heating System

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polyethylene bag
Description: polyethylene food bag
Study: NCT00744666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 1% topical eye drops
Description: Prednisolone 1% 1gtt qid to the eye requiring IVTA
Study: NCT01077193

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastric Plication
Description: A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
Study: NCT01468389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 900-1000mg/m2 bid, days 1-14, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
Study: NCT02203006

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: OVIHD
Description: 7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
Study: NCT03588949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement with L-carnitine (FertilHom)
Description: 1 stick of the TDS (vitamins, trace elements with carnitine) will be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Dietary Supplement
Description: 1 stick of the TDSwill be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
Study: NCT04665115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01407523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * Formulation: concentrate for solution for infusion~* Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~* Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~* Frequency: twice daily
Study: NCT01522404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
Study: NCT03734029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (DS-8201a)
Description: DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study: NCT01469637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfamethoxazole + MMX placebo
Description: 800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole + MMX Mesalazine/mesalamine
Description: 800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
Study: NCT03225027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional judgment task
Description: Participants had to indicate on a computer the emotional intensity of audio recordings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional judgment task
Description: Participants had to indicate on a computer the emotional intensity of audio recordings.
Study: NCT03788811

Intervention type: DEVICE
Intervention: ERG assessment (RSPA)
Description: Processing and analysis of retinal signals

Intervention type: DEVICE
Intervention: ERG assessment (RSPA)
Description: Processing and analysis of retinal signals
Study: NCT03734029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study: NCT03225027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional judgment task
Description: Participants had to indicate on a computer the emotional intensity of audio recordings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-experimental questionnaire
Description: Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-experimental questionnaire
Description: Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
Study: NCT03734029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study: NCT03156959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-Eb
Description: The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-Eb
Description: The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself.
Study: NCT04921540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ingrown toenails with surgery with chemical cauterisation
Description: Removal of the ingrown lateral part of the toenail and chemical cauterisation
Study: NCT03225027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-experimental questionnaire
Description: Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
Study: NCT00227513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study: NCT03225027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recognition task
Description: Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recognition task
Description: Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recognition task
Description: Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detection task
Description: Participants indicate every time they heard a given sound in order to verify their audition level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detection task
Description: Participants indicate every time they heard a given sound in order to verify their audition level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detection task
Description: Participants indicate every time they heard a given sound in order to verify their audition level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAPE-42
Description: This questionnaire allows evaluating the nature of psychotic experiences.
Study: NCT04921540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ingrown toenails with only surgery
Description: Removal of the ingrown lateral part of the toenail with directed Healing pad
Study: NCT03822806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise in addition to Patching
Description: Patch for 2 hours a day, and exercise for the first 30 minutes of those 2 hours using the video game
Study: NCT02188459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
Study: NCT03974672

Intervention type: PROCEDURE
Intervention: Re-laparotomy

Intervention type: PROCEDURE
Intervention: Re-laparotomy
Study: NCT02359214

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
Study: NCT04084262

Intervention type: DEVICE
Intervention: Intramedullary Nail
Description: Subjects undergo a Lapidus Arthrodesis procedure combined with a supinating reduction technique to create a multi-plane correction of hallux valgus
Study: NCT03305172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Giving different structures of long term (36 weeks) financial incentives to increase physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Giving different structures of long term (36 weeks) financial incentives to increase physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Giving different structures of long term (36 weeks) financial incentives to increase physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Giving different structures of long term (36 weeks) financial incentives to increase physical activity
Study: NCT00470483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment during 8 weeks
Description: comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine treatment during 8 weeks
Description: treatment drug
Study: NCT01828021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Margetuximab
Description: Anti-HER2 monoclonal antibody
Study: NCT02442557

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injection
Study: NCT02359214

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100% Lactose tablet daily over 8 weeks (56 days).
Study: NCT02442557

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: intravenous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: intravenous injection
Study: NCT03535636

Intervention type: OTHER
Intervention: Polysomnography
Description: Sleep architecture will be assessed by polysomnography

Intervention type: OTHER
Intervention: Polysomnography
Description: Sleep architecture will be assessed by polysomnography
Study: NCT03582813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-directed care
Description: Traditional and non-traditional behavioral health services are chosen from within and outside the public mental health system

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: Traditional behavioral health services are chosen from along those delivered at the patient's community mental health agency
Study: NCT01947114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study: NCT02364648

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Mitochondria targeted antioxidant

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00135278

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CSF Drainage
Description: See Detailed Description

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No CSF Drainage
Description: See Detailed Description
Study: NCT02290548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: High flow nasal cannula used in postextubation patients

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: high flow nasal cannula
Description: High flow nasal cannula used in postextubation patients
Study: NCT04794660

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HPV DNA Test
Description: Screening for HPV using a HPV DNA test
Study: NCT04263740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Taping for 3 days every week and two sessions of PT twice a week. The PI also instructed the patient to inform him if the tape gets off or become loose. KT was removed after 72 hours, and then reapplied after a few days rest to allow the skin to recover and to avoid skin irritation. The patient was instructed to refrain from getting the tape wet for 30 to 45 minutes after application to allow for better adherence. Patients were also instructed to be careful during dressing and undressing so the tape does not get caught with their clothes if the edges of the tape get slightly loose. No physical therapy treatment or taping was provided during the rest period except for the prescribed home exercise program. Patients in both groups received the same traditional physical therapy treatment two times a week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Physical therapy
Description: Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises. Patient education focused on the natural history of the condition and its favorable prognosis, positive thinking, and encouragement of activity participation. Patient education was delivered through one-on-one discussion by the principal investigator.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional Physical therapy
Description: Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises. Patient education focused on the natural history of the condition and its favorable prognosis, positive thinking, and encouragement of activity participation. Patient education was delivered through one-on-one discussion by the principal investigator.
Study: NCT03225027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAPE-42
Description: This questionnaire allows evaluating the nature of psychotic experiences.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAPE-42
Description: This questionnaire allows evaluating the nature of psychotic experiences.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trait Emotional Intelligence Questionnaire
Description: To evaluate their emotional intelligence.
Study: NCT02692599

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: control live attenuated mumps vaccine
Description: The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
Study: NCT02457923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone counselling
Description: i) Data collection and counselling by ASHA using the cell application (App) developed by CommCare Dimagi ii) Mobile phone counselling iii) Routine counselling schedules